QIAGEN stated that it plans to integrate Ingenuity’s bioinformatics products with its solutions, including its GeneGlobe content portal, to create workflows for sample preparation to data interpretation. Based in California, with 120 employees, Ingenuity’s offerings also include Pathways Analysis for use with high-throughput analysis platforms, Variant Analysis for next-generation sequencing (NGS) data and iReport for gene expression experiments. It is also developing an NGS solution for molecular diagnostics for interpreting and scoring clinical variants.
Hilden, Germany and Redwood City, CA 4/29/13—QIAGEN has acquired Ingenuity Systems for $105 million in cash, effective April 29. Ingenuity is a provider of software solutions for the analysis and interpretation of the biological meaning of genomics data, including Knowledge Base, an expert-curated database of genomic variations and disease models. Ingenuity had 2012 sales of $20 million. “We are looking forward to expanding the seamless integration of leading biomedical information solutions into our full range of molecular testing solutions, thereby providing our customers a unique experience from sample to interpreted result and recommendations for next steps,” stated QIAGEN CEO Peer M. Schatz. In 2013, QIAGEN expects to report adjusted net sales (non-GAAP basis) of around $15 million from Ingenuity. The acquisition is expected to be dilutive to 2013 adjusted diluted EPS by $0.03 per share and to 2014 adjusted diluted EPS by $0.02 per share. It is expected to become accretive in 2015.